Kidney Research and Clinical Practice 2018 Dec; 37(4): 426-426  https://doi.org/10.23876/j.krcp.2018.37.3.248.corr
Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy [Volume 37, Issue 3, September 2018, Pages 248–256]
Eun Joo Song1, Kye Hwa Jeong2, Young Ae Yang2, Jeong-Hoon Lim2, Hee-Yeon Jung2, Ji-Young Choi2, Jang-Hee Cho2, Chan-Duck Kim2, Yong-Lim Kim2, and Sun-Hee Park2
1Department of Internal Medicine, Daehyun Chumdan Geriatric Hospital, Daegu, Korea, 2Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
Correspondence to: Sun-Hee Park, Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. E-mail: sh-park@knu.ac.kr. ORCID: https://orcid.org/0000-0002-0953-3343
Published online: December 31, 2018.
© The Korean Society of Nephrology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Body

In the above article (https://doi.org/10.23876/j.krcp.2018.37.3.248), there was an error in Figure 3. The authors regret this error, and the corrected figure is now presented below.

Kaplan-Meier analysis of anti-PLA2R antibody level and probability of renal survival (chronic kidney disease stage ≥ 3) (A), cumulative probability of complete remission (B) and spontaneous remission (C).

Anti-PLA2R ab, anti-phospholipase A2 receptor antibody.

The authors would like to apologize for any inconvenience.



e-submission

This Article


Cited By Articles
  • CrossRef (0)
  • PMC (0)
  • SCOPUS (0)

Services
Social Network Service

Archives

Indexed/Covered by